FDA Approves Natalizumab For Sandoz And Polpharma Biologics
Tyruko Biosimilar Rival To Tysabri Approved In US Following Recent European Nod
Sandoz and Polpharma Biologics have obtained US Food and Drug Administration approval for their Tyruko natalizumab biosimilar rival to Biogen’s Tysabri. The approval follows a recent endorsement from the European Medicines Agency.
